{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T18:46:16Z","timestamp":1782413176035,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Discordance between growth hormone (GH) and insulin-like growth factor-1 (IGF-1), where one hormone is within the age- and sex-adjusted reference and the other is not, can be observed in patients with acromegaly. The discrepancy complicates the interpretation of disease activity, thereby presenting a significant challenge in the clinical management of acromegaly. This study aimed to assess postoperative discordance prevalence and clinical correlates to clarify the implication of discordance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study describes a cohort of patients that has undergone pituitary surgery at Sahlgrenska University Hospital between 1994 and 2019 due to acromegaly. Medical records were reviewed and the group with postoperative discordant hormones was compared with the group with concordant hormones.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In a cohort of 82 patients surgically treated for acromegaly and thereafter examined with an oral glucose tolerance test (OGTT), 16 (19.5%) exhibited biochemical discordance. Fourteen of 16 patients showed elevated IGF-1 but normal GH. The IGF-1 levels at diagnosis were significantly higher in patients with discordance compared with the controlled concordant group. However, no differences were observed between the discordant and the concordant group regarding the baseline variables at diagnosis: age, gender, invasive tumour, micro\/macro-adenoma or BMI, nor hypertensive treatment at time of surgery and postoperative radiotherapy or reoperation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The prevalence of biochemical discordance in our cohort was 19.5%. The predominant pattern was elevated IGF-1 levels with a normal nadir GH. The discordant group had higher IGF-1 at diagnosis, suggesting that greater preoperative disease activity may predispose to postoperative biochemical discordance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-026-01694-6","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T19:53:08Z","timestamp":1779565988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and patterns of biochemical discordance in patients with surgically treated acromegaly"],"prefix":"10.1007","volume":"29","author":[{"given":"Anna","family":"Pennlund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Olsson Bontell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Skoglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Car\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudmundur","family":"Johannsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"11","key":"1694_CR1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S (2022) Acromegaly: pathogenesis, diagnosis, and management. lancet Diabetes Endocrinol 10(11):804\u2013826","journal-title":"lancet Diabetes Endocrinol"},{"issue":"19","key":"1694_CR2","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMra2409076","volume":"393","author":"A Giustina","year":"2025","unstructured":"Giustina A, Colao A (2025) Acromegaly. N Engl J Med 393(19):1926\u20131939","journal-title":"N Engl J Med"},{"issue":"4","key":"1694_CR3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s11102-011-0369-1","volume":"15","author":"JA Brzana","year":"2012","unstructured":"Brzana JA, Yedinak CG, Delashaw JB, Gultelkin HS, Cook D, Fleseriu M (2012) Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly na\u00efve to medical therapy and radiation: what to follow, GH or IGF-1 values? Pituitary 15(4):562\u2013570","journal-title":"Pituitary"},{"issue":"4","key":"1694_CR4","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1210\/jc.2007-2104","volume":"93","author":"O Alexopoulou","year":"2008","unstructured":"Alexopoulou O, Bex M, Abs R, T\u2019Sjoen G, Velkeniers B, Maiter D (2008) Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 93(4):1324\u20131330","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1694_CR5","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1210\/jc.2008-1337","volume":"94","author":"A Bianchi","year":"2009","unstructured":"Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A et al (2009) Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94(6):2015\u20132022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1694_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11102-025-01547-8","volume":"28","author":"D Emmanouilidis","year":"2025","unstructured":"Emmanouilidis D, Polanski W, Juratli T, Sobottka SB, Tsourdi E, Gruber M et al (2025) Predictive factors for post-therapeutic biochemical discordance in acromegaly: a monocentric analysis of 156 cases. Pituitary 28(4):74","journal-title":"Pituitary"},{"issue":"5","key":"1694_CR7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/cen.13129","volume":"85","author":"GA Kanakis","year":"2016","unstructured":"Kanakis GA, Chrisoulidou A, Bargiota A, Efstathiadou ZA, Papanastasiou L, Theodoropoulou A et al (2016) The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta-analysis. Clin Endocrinol 85(5):681\u2013688","journal-title":"Clin Endocrinol"},{"key":"1694_CR8","doi-asserted-by":"publisher","first-page":"101467","DOI":"10.1016\/j.ghir.2022.101467","volume":"64","author":"C Peixe","year":"2022","unstructured":"Peixe C, S\u00e1nchez-Garc\u00eda M, Grossman AB, Korbonits M, Marques P (2022) Biochemical discrepancies in the evaluation of the somatotroph axis: Elevated GH or IGF-1 levels do not always diagnose acromegaly. Growth Horm IGF Res 64:101467","journal-title":"Growth Horm IGF Res"},{"issue":"1","key":"1694_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11102-017-0792-z","volume":"20","author":"K Schilbach","year":"2017","unstructured":"Schilbach K, Strasburger CJ, Bidlingmaier M (2017) Biochemical investigations in diagnosis and follow up of acromegaly. Pituitary 20(1):33\u201345","journal-title":"Pituitary"},{"issue":"4","key":"1694_CR10","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1210\/jc.2007-2084","volume":"93","author":"AM Arafat","year":"2008","unstructured":"Arafat AM, M\u00f6hlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J et al (2008) Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 93(4):1254\u20131262","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1694_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.krcp.2011.12.005","volume":"31","author":"Y Oh","year":"2012","unstructured":"Oh Y (2012) The insulin-like growth factor system in chronic kidney disease: pathophysiology and therapeutic opportunities. Kidney Res Clin Pract 31(1):26\u201337","journal-title":"Kidney Res Clin Pract"},{"issue":"2","key":"1694_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1530\/eje.1.02218","volume":"155","author":"JW Chen","year":"2006","unstructured":"Chen JW, Nielsen MF, Caumo A, Vilstrup H, Christiansen JS, Frystyk J (2006) Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis. Eur J Endocrinol 155(2):285\u2013292","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1694_CR13","doi-asserted-by":"publisher","first-page":"bvad051","DOI":"10.1210\/jendso\/bvad051","volume":"7","author":"N Shoung","year":"2023","unstructured":"Shoung N, Ho KKY (2023) Managing estrogen therapy in the pituitary patient. J Endocr Soc 7(5):bvad051","journal-title":"J Endocr Soc"},{"issue":"3","key":"1694_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1530\/eje.1.02341","volume":"156","author":"AN Paisley","year":"2007","unstructured":"Paisley AN, Hayden K, Ellis A, Anderson J, Wieringa G, Trainer PJ (2007) Pegvisomant interference in GH assays results in underestimation of GH levels. Eur J Endocrinol 156(3):315\u2013319","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1694_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jfma.2017.02.014","volume":"117","author":"S Zhang","year":"2018","unstructured":"Zhang S, Li Y, Guo X, Gao L, Lian W, Yao Y et al (2018) Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly. J Formos Med Association = Taiwan yi zhi 117(1):34\u201341","journal-title":"J Formos Med Association = Taiwan yi zhi"},{"issue":"3","key":"1694_CR16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1210\/clinem\/dgaa859","volume":"106","author":"C Campana","year":"2021","unstructured":"Campana C, Cocchiara F, Corica G, Nista F, Arvigo M, Amar\u00f9 J et al (2021) Discordant GH and IGF-1 results in treated acromegaly: impact of GH cutoffs and mean values assessment. J Clin Endocrinol Metab 106(3):789\u2013801","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1694_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1227\/01.neu.0000431480.87160.84","volume":"73","author":"MS Shin","year":"2013","unstructured":"Shin MS, Yu JH, Choi JH, Jung CH, Hwang JY, Cho YH et al (2013) Long-term changes in serum IGF-1 levels after successful surgical treatment of growth hormone-secreting pituitary adenoma. Neurosurgery 73(3):473\u2013479","journal-title":"Neurosurgery"},{"issue":"2","key":"1694_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11102-025-01503-6","volume":"28","author":"A Pennlund","year":"2025","unstructured":"Pennlund A, Esposito D, Bontell TO, Skoglund T, Hall\u00e9n T, Car\u00e9n H et al (2025) Long-term clinical outcome of 103 patients with acromegaly after pituitary surgery. Pituitary 28(2):33","journal-title":"Pituitary"},{"issue":"2","key":"1694_CR19","first-page":"526","volume":"85","author":"A Giustina","year":"2000","unstructured":"Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K et al (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85(2):526\u2013529","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1694_CR20","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141\u20133148","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1694_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/eje.1.02186","volume":"155","author":"PJ Trainer","year":"2006","unstructured":"Trainer PJ, Barth J, Sturgeon C, Wieringaon G (2006) Consensus statement on the standardisation of GH assays. Eur J Endocrinol 155(1):1\u20132","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 4","key":"1694_CR22","first-page":"228s","volume":"9","author":"PT James","year":"2001","unstructured":"James PT, Leach R, Kalamara E, Shayeghi M (2001) The worldwide obesity epidemic. Obes Res 9(Suppl 4):228s\u201333s","journal-title":"Obes Res"},{"issue":"3","key":"1694_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-2265.2006.02430.x","volume":"64","author":"AL Espinosa-de-Los-Monteros","year":"2006","unstructured":"Espinosa-de-Los-Monteros AL, Sosa E, Cheng S, Ochoa R, Sandoval C, Guinto G et al (2006) Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status. Clin Endocrinol 64(3):245\u2013249","journal-title":"Clin Endocrinol"},{"key":"1694_CR24","doi-asserted-by":"publisher","first-page":"1256975","DOI":"10.3389\/fendo.2023.1256975","volume":"14","author":"M Romanisio","year":"2023","unstructured":"Romanisio M, Pitino R, Ferrero A, Pizzolitto F, Costelli S, Antoniotti V et al (2023) Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study. Front Endocrinol 14:1256975","journal-title":"Front Endocrinol"},{"issue":"1","key":"1694_CR25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s12020-020-02387-1","volume":"70","author":"V Amodru","year":"2020","unstructured":"Amodru V, Petrossians P, Colao A, Delemer B, Maione L, Neggers S et al (2020) Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey database. Endocrine 70(1):134\u2013142","journal-title":"Endocrine"},{"key":"1694_CR26","doi-asserted-by":"crossref","unstructured":"Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek J et al (2005) Accuracy of body mass index in diagnosing obesity in the adult general population. International journal of obesity 2008;32(6):959\u2009\u2013\u200966","DOI":"10.1038\/ijo.2008.11"},{"issue":"11","key":"1694_CR27","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","volume":"21","author":"S Melmed","year":"2025","unstructured":"Melmed S, di Filippo L, Fleseriu M, Mercado M, Karavitaki N, Gurnell M et al (2025) Consensus on acromegaly therapeutic outcomes: an update. Nat reviews Endocrinol 21(11):718\u2013737","journal-title":"Nat reviews Endocrinol"},{"issue":"8","key":"1694_CR28","first-page":"2646","volume":"83","author":"S Melmed","year":"1998","unstructured":"Melmed S, Jackson I, Kleinberg D, Klibanski A (1998) Current treatment guidelines for acromegaly1. J Clin Endocrinol Metabolism 83(8):2646\u20132652","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"6","key":"1694_CR29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1530\/EJE-20-0019","volume":"182","author":"D Esposito","year":"2020","unstructured":"Esposito D, Ragnarsson O, Johannsson G, Olsson DS (2020) Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol 182(6):523\u2013531","journal-title":"Eur J Endocrinol"},{"key":"1694_CR30","doi-asserted-by":"crossref","unstructured":"Giustina A, Fleseriu M (2026) Acromegaly complications: an update. The Journal of clinical endocrinology and metabolism","DOI":"10.1210\/clinem\/dgag114"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01694-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01694-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01694-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:49:15Z","timestamp":1782409755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-026-01694-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1694"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01694-6","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Swedish Ethical Review Authority (Etikpr\u00f6vningsmyndigheten) (Dnr: 2019-04779).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"A.P., T.O.B., H.C. and T.S. has no conflict of interest to declare. D.S.O. is an employee at AstraZeneca as of 30 August 2021. G.J. has served as a consultant for Novo Nordisk, Crinetics, and AstraZeneca and has received lecture fees from Ascendis Pharma, Novo Nordisk, Pfizer, and Pharmanova. D.E. has received lecture fees from Ipsen, Recordati, and Pfizer AB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}